Feedback
Join Now | Sign in
My Healthline
Free Newsletters
 

Drug Notebook

Generic Name: ibuprofen

View All Brands
NeoProfen, Midol IB, Motrin Childrens, Ibu-Tab, Saleto-400, Menadol, Advil, Motrin IB, Ibu-8, Midol, Pediacare Fever, Advil Childrens, Advil Migraine, Advil Liquigel, Ibuprofen Dye Free, Advil Pediatric, Childrens Ibuprofen Berry, Haltran, Q-Profen, Motrin, Saleto-600, Motrin Junior Strength, Genpril, Saleto-200, Motrin Infant Drops, Ibu-4, Wal-Profen, Advil Junior Strength, Motrin Migraine Pain, Saleto-800, Rufen, Ibuprofen Infant's Drops, Ibu-6, Midol Maximum Strength Cramp Formula, Ibu, IBU-200, Ibuprofen Childrens, Ibuprofen PMR, Nuprin
An NSAID - treats Cystic Fibrosis, Fever, Dysmenorrhea, Acute Gout, Headache, Rheumatoid Arthritis, ... more
Search Drug Notebook
Hide
Your search results:
Search the ibuprofen Drug Notebook
FDA Alerts

Special Alerts:

[Posted 01/17/2008] FDA informed consumers and healthcare professionals that the Agency has completed its review of information regarding the safety of over-the-counter (OTC) cough and cold medicines in children under 2 years of age and recommends that these drugs not be used to treat children in this age group because serious and potentially life-threatening side effects can occur. FDA's recommendation is based on both the review of the information the Agency received about serious side effects in children in the referenced age group and the discussion and recommendations made at the October 18 -19, 2007, public advisory committee meeting at which this issue was discussed. FDA has not completed its review of information about the safety of OTC cough and cold medicines in children 2 through 11 years of age. See the FDA Public Health Advisory for Agency recommendations regarding this issue. For more information visit the FDA website at: http://www.fda.gov/medwatch/safety/2008/safety08.htm#cough and http://www.fda.gov/cder/drug/advisory/cough_cold_2008.htm.

Media Gallery
Drug Info Tools
Pill Finder
Search by color, shape and markings. click here
Drug Interaction Checker
Check any 2 drugs for interactions. click here
Drug Compare
Compare any two drugs side by side. click here
Healthline Part D Plan Selector Medicare Part D
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
Advertisement
Marketplace
Licensed from
ibuprofen
Page: < Back 1 2 3 4 Next >
(eye byoo PROE fen)

Drug Interactions

No evidence of enzyme induction.

Specific Drugs

Drug Interaction Comments
ACE inhibitors

Reduced BP response to ACE inhibitor

Possible deterioration of renal function in individuals with renal impairment

 Monitor BP
Alcohol Increased risk of GI bleeding
Angiotensin II receptor antagonists

Reduced BP response to angiotensin II receptor antagonist

Possible deterioration of renal function in individuals with renal impairment

 Monitor BP
Antacids (aluminum- and magnesium-containing) No effect on ibuprofen absorption
Aspirin

Antagonism of the irreversible platelet-aggregation inhibitory effect of aspirin; may limit the cardioprotective effects of aspirin

Increased risk of GI ulceration and other complications

No consistent evidence that low-dose aspirin mitigates the increased risk of serious cardiovascular events associated with NSAIAs

Manufacturer states that concomitant use not recommended

Regular ibuprofen use not recommended in patients taking aspirin for cardiovascular prophylaxis

For occasional use with immediate-release low-dose aspirin: Administer single dose of ibuprofen 400 mg for self-medication at least 8 hours before or at least 30 minutes after aspirin

Enteric-coated low-dose aspirin: No recommendations regarding timing of administration with single dose of ibuprofen

Diuretics (furosemide, thiazides) Reduced natriuretic effects Monitor for diuretic efficacy and renal failure
H2 antagonists (cimetidine, ranitidine) Serum ibuprofen concentrations not appreciably altered
Lithium Increased plasma lithium concentrations Monitor for lithium toxicity; monitor lithium concentrations; lithium dosage reduction may be required
Methotrexate Pharmacokinetics of methotrexate may be altered Caution advised
Warfarin Reports of bleeding Caution advised

Pharmacokinetics

Absorption

Bioavailability

Well absorbed following oral administration; peak plasma concentration usually attained within 1–2 hours.

Onset

Pain relief and/or antipyretic activity achieved within 1 hour.

Food

Food reduces peak plasma concentration by about 30–50% and delays time to reach peak plasma concentration by about 30–60 minutes but does not affect extent of absorption.

Distribution

Plasma Protein Binding

>99%.

Elimination

Metabolism

Extensively metabolized.

Elimination Route

Excreted mainly in urine as metabolites.

Half-life

1.8–2 hours.

Half-life 10-fold longer in neonates than in adults.

Stability

Storage

Oral

Capsules and Tablets

20–25°C.

Suspension

20–25°C.

Actions

  • Inhibits cyclooxygenase-1 (COX-1) and COX-2.
  • Pharmacologic actions similar to those of other prototypical NSAIAs; exhibits anti-inflammatory, analgesic, and antipyretic activity.
  • Permits closure of the ductus arteriosus in premature neonates by inhibiting prostaglandin synthesis.

Advice to Patients

Pending revision, the material in this section should be considered in light of more recently available information in the MEDWATCH notification at the beginning of this monograph.

  • Importance of reading the medication guide for NSAIAs that is provided each time the drug is dispensed.
  • When used for self-medication, importance of reading the product labeling.
  • When used for self-medication, importance of using the lowest effective dosage and of not exceeding the recommended dosage or duration of therapy.
  • When used for self medication, importance of reviewing the warning information provided by the manufacturer.
  • Risk of serious cardiovascular events with long-term use.
  • Risk of GI bleeding and ulceration.
  • Risk of serious skin reactions. Risk of anaphylactoid and other sensitivity reactions.
  • Risk of hepatotoxicity.
  • Importance of notifying clinician if signs and symptoms of a cardiovascular event (chest pain, dyspnea, weakness, slurred speech) occur.
  • Importance of notifying clinician if signs and symptoms of GI ulceration or bleeding, unexplained weight gain, or edema develops.
  • Importance of discontinuing ibuprofen and contacting clinician if rash or other signs of hypersensitivity (blisters, fever, pruritus) develop. Importance of seeking immediate medical attention if an anaphylactic reaction occurs.
  • Importance of discontinuing therapy and contacting clinician immediately if signs and symptoms of hepatotoxicity (nausea, fatigue, lethargy, pruritus, jaundice, upper right quadrant tenderness, flu-like symptoms) occur.
  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed. Importance of avoiding ibuprofen in late pregnancy (third trimester).
  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.
  • Importance of informing patients of other important precautionary information. (See Cautions.)

Page: < Back 1 2 3 4 Next >
Uses Dosage and Administration Cautions Drug Interactions Pharmacokinetics Stability Actions Advice to Patients Preparations
Related Learning
Centers
·As a Drug
ACL Tear
Achilles Tendonitis
Ankylosing Spondylitis
Arterial Embolism
Arthritis
Back Disorders
Back Pain
Bilateral Cataracts
Broken Nose
Bursitis
Carpal Tunnel Syndrome
Cataract
Cellulitis
Cervical Disc Degeneration
Cervical Spondylosis
Charcot Marie Tooth Disease
Chondromalacia
Chronic Fatigue Syndrome (CFS)
Chronic Gout
Costochondritis

Advertisement
Back to Top